Actively Recruiting
Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment
Led by Emory University · Updated on 2026-01-30
5
Participants Needed
2
Research Sites
98 weeks
Total Duration
On this page
Sponsors
E
Emory University
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This clinical trial studies how well ganglion impar neurolysis works to improve radiation-induced pain during the treatment of anal or perianal skin cancer that has not spread to other parts of the body (localized). Treatment for anal or perianal skin cancer includes giving chemotherapy and radiation therapy (CRT) at the same time. CRT is frequently associated with several side effects, including radiation-induced pain. Despite advances in radiation therapy delivery, patients may still experience side effects which can lead to treatment breaks or treatment discontinuation. Ganglion impar neurolysis is a type of nerve block procedure in which medicine is injected directly into or around a nerve to block pain. The location of the procedure is near the tail bone and the medicine numbs the nerves that are in charge of sensation in the skin by the buttocks and genitalia. This may improve radiation-induced pain in patients receiving CRT for localized anal or perianal skin cancer.
CONDITIONS
Official Title
Ganglion Impar Neurolysis for the Improvement of Radiation-Induced Pain During Localized Anal or Perianal Skin Cancer Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with localized anal or perianal skin cancer and either started or about to start definitive chemotherapy and radiation therapy
- Reporting pain scores of 5 or higher, or experiencing high pain interference or distress
- At least 18 years old
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less (Karnofsky score over 60%)
- Life expectancy greater than 12 months
- Able to understand and willing to sign informed consent
- Men and women of all races and ethnic groups are eligible
- Willing and able to complete questionnaires
- Previous cancer diagnosis such as colon or previously resected anal cancer allowed
- HIV diagnosis or immunocompromised status allowed
You will not qualify if you...
- Absolute neutrophil count less than 1500
- Platelet count less than 80,000
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States, 30322
Actively Recruiting
2
Grady Health System
Atlanta, Georgia, United States, 30322
Actively Recruiting
Research Team
J
Jolinta Y. Lin, MD
CONTACT
V
Vinita Singh, MD, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here